All Stories

  1. Development of the Lung Transplant Frailty Scale (LT-FS)
  2. Radiographic Lung Abnormalities in First-Degree Relatives of Patients With Different Subtypes of Pulmonary Fibrosis
  3. Selective serotonin reuptake inhibitors and lung function in the multi-ethnic study of atherosclerosis lung study
  4. Summary for Clinicians: Clinical Practice Guideline on Home Oxygen Therapy for Adults with Chronic Lung Disease
  5. Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline
  6. Deep Learning of CT Virtual Wedge Resection for Prediction of Histologic Usual Interstitial Pneumonitis
  7. Regional distribution of high-attenuation areas on chest computed tomography in the Multi-Ethnic Study of Atherosclerosis
  8. Donor surfactant protein A2 polymorphism and lung transplant survival
  9. Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis
  10. Angiotensin Receptor Blockers and Subclinical Interstitial Lung Disease: The MESA Study
  11. Risk factors for disease progression in idiopathic pulmonary fibrosis
  12. Concomitant Medications and Clinical Outcomes in Idiopathic Pulmonary Fibrosis
  13. Growth differentiation factor-15 as a biomarker of strength and recovery in survivors of acute respiratory failure
  14. Circulating adhesion molecules and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis
  15. Aryl-Hydrocarbon Receptor Repressor Gene in Primary Graft Dysfunction after Lung Transplantation
  16. Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation
  17. Cryobiopsy for Interstitial Lung Disease: The Heat Is On
  18. AnnalsATS: New Developments and Advice for Authors
  19. The Annals of the American Thoracic Society Editorial Fellowship Program
  20. More on Causal Inference Studies
  21. Reply: Ethics of Health Research Supported by For-Profit Cannabis Companies: What Have We Learned from Big Tobacco?
  22. Procedure Preference and Intention-to-Treat Outcomes after Listing for Lung Transplantation among U.S. Adults. A Cohort Study
  23. Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals
  24. Reply
  25. 2018 Clinical Practice Guideline Summary For Practicing Clinicians: Diagnosis of Idiopathic Pulmonary Fibrosis
  26. Optimizing Home Oxygen Therapy. An Official American Thoracic Society Workshop Report
  27. The Phillip Morris Foundation for a Smoke-Free World. A Cause for Concern
  28. Bidirectional transfer of Anelloviridae lineages between graft and host during lung transplantation
  29. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
  30. Idiopathic Pulmonary Fibrosis
  31. Screening high-resolution computed tomography of the chest to detect interstitial lung disease in systemic sclerosis: a global survey of rheumatologists
  32. Quantitative Evidence for Revising the Definition of Primary Graft Dysfunction after Lung Transplant
  33. AnnalsATS 2022: Rigor, Value, Impact
  34. Serum Matrix Metalloproteinase-7, Respiratory Symptoms, and Mortality in Community-Dwelling Adults. MESA (Multi-Ethnic Study of Atherosclerosis)
  35. A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective
  36. Associations between emphysema-like lung on CT and incident airflow limitation: a general population-based cohort study
  37. Occupational Exposures and Subclinical Interstitial Lung Disease. The MESA (Multi-Ethnic Study of Atherosclerosis) Air and Lung Studies
  38. Clinical Risk Factors and Prognostic Model for Primary Graft Dysfunction after Lung Transplantation in Patients with Pulmonary Hypertension
  39. A novel patient-centered “intention-to-treat” metric of U.S. lung transplant center performance
  40. Patient-centered Outcomes in Idiopathic Pulmonary Fibrosis Clinical Trials
  41. Race, Ethnicity, Health Insurance, and Mortality in Older Survivors of Critical Illness
  42. Genome-wide association study of subclinical interstitial lung disease in MESA
  43. Antacid use and subclinical interstitial lung disease: the MESA study
  44. Plasma Soluble Receptor for Advanced Glycation End Products in Idiopathic Pulmonary Fibrosis
  45. Diagnosing idiopathic pulmonary fibrosis without a lung biopsy: honeycombing not required
  46. The Frailty Phenotype and Palliative Care Needs of Older Survivors of Critical Illness
  47. Peripheral Blood Gene Expression Changes Associated With Primary Graft Dysfunction After Lung Transplantation
  48. Cholesterol, lipoproteins and subclinical interstitial lung disease: the MESA study
  49. Chest Fat Quantification via CT Based on Standardized Anatomy Space in Adult Lung Transplant Candidates
  50. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis
  51. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial
  52. The Perioperative Lung Transplant Virome: Torque Teno Viruses Are Elevated in Donor Lungs and Show Divergent Dynamics in Primary Graft Dysfunction
  53. Primary graft dysfunction: Long-term physical function outcomes among lung transplant recipients
  54. The Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation
  55. Rheumatoid arthritis-associated autoantibodies and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis
  56. Adipose Gene Expression Profile Changes With Lung Allograft Reperfusion
  57. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
  58. Novel Picture Guide for Spiritual Care in the ICU
  59. Frailty in Pulmonary and Critical Care Medicine
  60. Polysomnographic Measurement of Sleep Duration and Bodily Pain Perception in the Sleep Heart Health Study
  61. High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study
  62. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function
  63. Living with Interstitial Lung Disease: How Do We Best Meet the Educational Needs of Our Patients?
  64. Donor lung assessment using selective pulmonary vein gases
  65. Impact of the Arg 16 allele of the B2AR gene on the effect of withdrawal of LABA in patients with moderate to severe asthma
  66. Smoking and Subclinical ILD in RA versus the Multi-Ethnic Study of Atherosclerosis
  67. Per cent emphysema is associated with respiratory and lung cancer mortality in the general population: a cohort study
  68. The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia
  69. Fat quantification and analysis of lung transplant patients on unenhanced chest CT images based on standardized anatomic space
  70. Fat segmentation on chest CT images via fuzzy models
  71. Short stature and lung transplantation
  72. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
  73. Association of Forced Vital Capacity with the Developmental Gene NCOR2
  74. Seeking and sharing: why the pulmonary fibrosis community engages the web 2.0 environment
  75. Prognostic Significance of Biomarkers in Pulmonary Arterial Hypertension
  76. Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune RegulatorTOLLIPin Post-Lung Transplant Primary Graft Dysfunction Risk
  77. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
  78. Frailty Phenotypes, Disability, and Outcomes in Adult Candidates for Lung Transplantation
  79. Idiopathic Pulmonary Fibrosis in United States Automated Claims. Incidence, Prevalence, and Algorithm Validation
  80. A comparison of visual and quantitative methods to identify interstitial lung abnormalities
  81. Editors' Introduction toAnnalsATSClinical Research Design Articles
  82. Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis
  83. Survival of Adults With Systemic Sclerosis Following Lung Transplantation: A Nationwide Cohort Study
  84. Objective Estimates Improve Risk Stratification for Primary Graft Dysfunction after Lung Transplantation
  85. Interleukin-6 and Tumor Necrosis Factor-α Are Associated with Quality of Life–Related Symptoms in Pulmonary Arterial Hypertension
  86. Neutrophil Extracellular Traps Are Pathogenic in Primary Graft Dysfunction after Lung Transplantation
  87. A consensus document for the selection of lung transplant candidates: 2014—An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation
  88. Association Between Emphysema-like Lung on Cardiac Computed Tomography and Mortality in Persons Without Airflow Obstruction
  89. Body Composition and Mortality after Adult Lung Transplantation in the United States
  90. Embracing Complex Diseases. The Case for an Idiopathic Pulmonary Fibrosis Biorepository
  91. Intravenous Immunoglobulin for Hypogammaglobulinemia after Lung Transplantation: A Randomized Crossover Trial
  92. Genome-wide association analysis identifies six new loci associated with forced vital capacity
  93. Plasma Complement Levels Are Associated with Primary Graft Dysfunction and Mortality after Lung Transplantation
  94. The feasibility of measuring frailty to predict disability and mortality in older medical intensive care unit survivors
  95. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
  96. Interstitial Lung Disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases
  97. Genetic Variation in the Prostaglandin E2Pathway Is Associated with Primary Graft Dysfunction
  98. Preoperative Plasma Club (Clara) Cell Secretory Protein Levels Are Associated With Primary Graft Dysfunction After Lung Transplantation
  99. Erratum
  100. Lung Transplantation and Atrial Septostomy in Pulmonary Arterial Hypertension
  101. Clinical trials in idiopathic pulmonary fibrosis: a framework for moving forward
  102. High Burden of Palliative Needs among Older Intensive Care Unit Survivors Transferred to Post–Acute Care Facilities. A Single-Center Study
  103. Pilot Study Exploring Lung Allograft Surfactant Protein A (SP-A) Expression in Association With Lung Transplant Outcome
  104. Donor Age and Early Graft Failure After Lung Transplantation: A Cohort Study
  105. Latent Class Analysis Identifies Distinct Phenotypes of Primary Graft Dysfunction After Lung Transplantation
  106. Donor Surfactant Protein D (SP-D) Polymorphisms Are Associated With Lung Transplant Outcome
  107. Gene Set Enrichment Analysis Identifies Key Innate Immune Pathways in Primary Graft Dysfunction After Lung Transplantation
  108. Disparities in lung transplantation
  109. Pulmonary arteriole gene expression signature in idiopathic pulmonary fibrosis
  110. Preoperative Serum Albumin Levels Predict 1-Year Postoperative Survival of Patients Undergoing Heart Transplantation
  111. An Acute Change in Lung Allocation Score and Survival After Lung Transplantation
  112. A Prognostic Model for 6-Month Mortality in Elderly Survivors of Critical Illness
  113. Clinical Risk Factors for Primary Graft Dysfunction after Lung Transplantation
  114. Elevated Plasma Angiopoietin-2 Levels and Primary Graft Dysfunction after Lung Transplantation
  115. Plasma monocyte chemotactic protein-1 levels at 24 hours are a biomarker of primary graft dysfunction after lung transplantation
  116. Socioeconomic Barriers to Lung Transplantation
  117. Variation in PTX3 Is Associated with Primary Graft Dysfunction after Lung Transplantation
  118. A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation
  119. A comparison of single breath and re-breathe diffusing capacity in emphysema patients and controls
  120. Postoperative Estradiol Levels Associate With Development of Primary Graft Dysfunction in Lung Transplantation Patients
  121. Is Obstructive Sleep Apnea a Cause of Idiopathic Pulmonary Fibrosis?
  122. Secondary Prevention of Idiopathic Pulmonary Fibrosis: Catching the Horse Still in the Barn
  123. Sildenafil for Chronic Obstructive Pulmonary Disease: A Randomized Crossover Trial
  124. Hypoalbuminemia and Early Mortality After Lung Transplantation: A Cohort Study
  125. Selecting lung transplant candidates: where do current guidelines fall short?
  126. Pulmonary Capillary Wedge Pressure Augments Right Ventricular Pulsatile Loading
  127. Plasma Endothelin-1 and Vascular Endothelial Growth Factor Levels and Their Relationship to Hemodynamics in Idiopathic Pulmonary Fibrosis
  128. Translational Research in Lung Transplantation: How Do We Get From Mouse to Human?
  129. Two, One, or None for Chronic Obstructive Pulmonary Disease: Who Decides and How?
  130. Obesity and Primary Graft Dysfunction after Lung Transplantation
  131. Delayed Access and Survival in Idiopathic Pulmonary Fibrosis
  132. Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis
  133. Elevated Plasma Long Pentraxin-3 Levels and Primary Graft Dysfunction After Lung Transplantation for Idiopathic Pulmonary Fibrosis
  134. Effect of Single vs Bilateral Lung Transplantation on Plasma Surfactant Protein D Levels in Idiopathic Pulmonary Fibrosis
  135. Randomized Clinical Trial of Aspirin and Simvastatin for Pulmonary Arterial Hypertension: ASA-STAT
  136. Lung Volume Reduction Surgery Using the NETT Selection Criteria
  137. Elevated Pulmonary Artery Pressure Is a Risk Factor for Primary Graft Dysfunction Following Lung Transplantation for Idiopathic Pulmonary Fibrosis
  138. Rationale and design of a phase II clinical trial of aspirin and simvastatin for the treatment of pulmonary arterial hypertension: ASA-STAT
  139. Elevated Plasma Clara Cell Secretory Protein Concentration Is Associated with High-Grade Primary Graft Dysfunction
  140. Micromechanics of Alveolar Edema
  141. Construct validity of the definition of primary graft dysfunction after lung transplantation
  142. Vascular Inflammation in Obesity and Sleep Apnea
  143. Plasma Levels of Receptor for Advanced Glycation End Products, Blood Transfusion, and Risk of Primary Graft Dysfunction
  144. Obesity and Underweight Are Associated with an Increased Risk of Death after Lung Transplantation
  145. Cigarette Smoking Is Associated with Subclinical Parenchymal Lung Disease
  146. Soluble P-Selectin and the Risk of Primary Graft Dysfunction After Lung Transplantation
  147. Tacrolimus and Azathioprine Versus Cyclosporine and Mycophenolate Mofetil After Lung Transplantation: A Retrospective Cohort Study
  148. Circulating KL-6, a biomarker of lung injury, in obstructive sleep apnoea
  149. Serum Albumin Concentration and Waiting List Mortality in Idiopathic Interstitial Pneumonia
  150. Quantification of single-breath underestimation of lung volume in emphysema
  151. Platelets Enhance Endothelial Adhesiveness in High Tidal Volume Ventilation
  152. The Modification of Diet in Renal Disease (MDRD) and the Prediction of Kidney Outcomes After Lung Transplantation
  153. Assessment of Kidney Function in Lung Transplant Candidates
  154. Use of an Interferon-γ Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients
  155. Platelet activation in the postoperative period after lung transplantation
  156. Racial Differences in Waiting List Outcomes in Chronic Obstructive Pulmonary Disease
  157. Plasma serotonin levels are normal in pulmonary arterial hypertension
  158. Outcomes after Lung Retransplantation in the Modern Era
  159. Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis
  160. Update in Surgical Therapy for Chronic Obstructive Pulmonary Disease
  161. Risk Factors for Venous Thromboembolism After Lung Transplantation
  162. Lung-volume reduction surgery for pulmonary emphysema: Improvement in body mass index, airflow obstruction, dyspnea, and exercise capacity index after 1 year
  163. Racial and Ethnic Disparities in Idiopathic Pulmonary Fibrosis: A UNOS/OPTN Database Analysis
  164. Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension
  165. Six-Minute-Walk Distance Predicts Waiting List Survival in Idiopathic Pulmonary Fibrosis
  166. Immunoglobulin G Levels before and after Lung Transplantation
  167. Racial and Ethnic Disparities in Survival in Lung Transplant Candidates with Idiopathic Pulmonary Fibrosis
  168. Osteoporosis in Diffuse Parenchymal Lung Disease
  169. Successful Bilateral Lung Transplantation for Pulmonary Fibrosis Associated With the Hermansky-Pudlak Syndrome
  170. Outcomes of Extended Donor Lung Recipients after Lung Transplantation